PRECISE试验:基于风险分层的初始检查策略与常规检查在稳定胸痛疑似冠心病患者中的比较
PRECISE随机临床试验纳入2103例稳定症状疑似冠心病患者,比较精准策略(PS,基于PROMISE最小风险评分推迟低危者检查,其余行cCTA及选择性FFR-CT)与常规检查(UT)。主要复合终点(无阻塞性冠脉的导管检查+死亡/非致死性心梗)PS组4.2% vs UT组11.3%(HR 0.35,95%CI 0.25-0.50),主要驱动于减少无阻塞性病变的导管检查,安全复合终点无显著差异。
要点
- 精准策略使主要复合终点风险降低65%(HR 0.35),主要因减少无阻塞性冠脉的导管检查。
- 死亡/非致死性心梗复合终点两组无显著差异(HR 1.52,95%CI 0.73-3.15)。
- 精准策略组1年降脂药和抗血小板药使用率更高(均P<.001)。
核心结论
- 在稳定症状疑似冠心病患者中,初始精准策略较常规检查提高了临床效率,主要复合终点发生率更低。
研究设计与样本
- 来自65个北美和欧洲中心、稳定症状疑似冠心病且既往未检查的患者2103例,1:1随机分配至精准策略或常规检查。
主要发现
- 主要复合终点精准策略组44/1057(4.2%)vs 常规检查组118/1046(11.3%),HR 0.35(95%CI 0.25-0.50)。
- 无阻塞性病变的导管检查精准策略组27/1057(2.6%)vs 常规检查组107/1046(10.2%),HR 0.24(95%CI 0.16-0.36)。
- 死亡/非致死性心梗复合终点HR 1.52(95%CI 0.73-3.15);死亡HR 0.71(95%CI 0.23-2.23),非致死性心梗HR 2.65(95%CI 0.96-7.36)。
- 1年降脂药使用精准策略组450/900(50.0%)vs 常规检查组365/873(41.8%),抗血小板药321/900(35.7%)vs 237/873(27.1%),均P<.001。
关键数值与推荐
- 精准策略采用PROMISE最小风险评分定量筛选最小风险参与者推迟检查,其余行cCTA及选择性FFR-CT。
- 常规检查包括中心选择的负荷试验或导管检查。
临床怎么用
- 对稳定症状疑似冠心病患者,可先采用定量风险评分识别最小风险者推迟初始检查。
- 非最小风险者以cCTA作为初始检查,并根据需要选择性行FFR-CT。
- 该策略可减少无阻塞性冠脉的导管检查,但需关注非致死性心梗数值差异及额外随机试验验证安全性。
局限性
- 需额外随机临床试验验证这些发现,包括安全性。
- 非致死性心梗HR 2.65(95%CI 0.96-7.36)置信区间宽,需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Trials showing equivalent or better outcomes with initial evaluation using coronary computed tomography angiography (cCTA) compared with stress testing in patients with stable chest pain have informed guidelines but raise questions about overtesting and excess catheterization. OBJECTIVE: To test a modified initial cCTA strategy designed to improve clinical efficiency vs usual testing (UT). DESIGN, SETTING, AND PARTICIPANTS: This was a pragmatic randomized clinical trial enrolling participants from December 3, 2018, to May 18, 2021, with a median of 11.8 months of follow-up. Patients from 65 North American and European sites with stable symptoms of suspected coronary artery disease (CAD) and no prior testing were randomly assigned 1:1 to precision strategy (PS) or UT. INTERVENTIONS: PS incorporated the Prospective Multicenter Imaging Study for the Evaluation of Chest Pain (PROMISE) minimal risk score to quantitatively select minimal-risk participants for deferred testing, assigning all others to cCTA with selective CT-derived fractional flow reserve (FFR-CT). UT included site-selected stress testing or catheterization. Site clinicians determined subsequent care. MAIN OUTCOMES AND MEASURES: Outcomes were clinical efficiency (invasive catheterization without obstructive CAD) and safety (death or nonfatal myocardial infarction [MI]) combined into a composite primary end point. Secondary end points included safety components of the primary outcome and medication use. RESULTS: A total of 2103 participants (mean [SD] age, 58.4 [11.5] years; 1056 male [50.2%]) were included in the study, and 422 [20.1%] were classified as minimal risk. The primary end point occurred in 44 of 1057 participants (4.2%) in the PS group and in 118 of 1046 participants (11.3%) in the UT group (hazard ratio [HR], 0.35; 95% CI, 0.25-0.50). Clinical efficiency was higher with PS, with lower rates of catheterization without obstructive disease (27 [2.6%]) vs UT participants (107 [10.2%]; HR, 0.24; 95% CI, 0.16-0.36). The safety composite of death/MI was similar (HR, 1.52; 95% CI, 0.73-3.15). Death occurred in 5 individuals (0.5%) in the PS group vs 7 (0.7%) in the UT group (HR, 0.71; 95% CI, 0.23-2.23), and nonfatal MI occurred in 13 individuals (1.2%) in the PS group vs 5 (0.5%) in the UT group (HR, 2.65; 95% CI, 0.96-7.36). Use of lipid-lowering (450 of 900 [50.0%] vs 365 of 873 [41.8%]) and antiplatelet (321 of 900 [35.7%] vs 237 of 873 [27.1%]) medications at 1 year was higher in the PS group compared with the UT group (both P < .001). CONCLUSIONS AND RELEVANCE: An initial diagnostic approach to stable chest pain starting with quantitative risk stratification and deferred testing for minimal-risk patients and cCTA with selective FFR-CT in all others increased clinical efficiency relative to UT at 1 year. Additional randomized clinical trials are needed to verify these findings, including safety. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03702244.
引用
- Douglas PS, Nanna MG, Kelsey MD, et al. Comparison of an Initial Risk-Based Testing Strategy vs Usual Testing in Stable Symptomatic Patients With Suspected Coronary Artery Disease: The PRECISE Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 37610731. doi:10.1001/jamacardio.2023.2595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。